Press Releases

Emeryville, Calif. – March 14, 2022 Financing round led by returning investor ARCH Venture Partners Enables accelerated development of therapeutic pipeline built upon its proprietary RNA technology platform Industry veteran Michael F. Bigham appointed to the board of directors Nutcracker Therapeutics, Inc., a biotech company developing RNA therapeutics using its proprietary biochip-based manufacturing platform, today […]

Emeryville, Calif. – September 23, 2020 Financing led by ARCH Venture Partners Company aims to efficiently develop, manufacture and deliver mRNA medicines to patients worldwide using its proprietary push-button “GMP-in-a-box” system Company will initially focus on developing first-in-class mRNA therapeutics for oncology indications and forging collaborations with biotech and pharma companies Nutcracker Therapeutics, Inc., a […]

Emeryville, Calif. – September 23, 2020 – Nutcracker Therapeutics, Inc., a company developing and producing mRNA therapeutics on its proprietary, microfluidic, biochip-based platform, today announced the appointment of Madhavan (“Madhu”) Balachandran, former executive vice president of operations at Amgen, as chief operating officer. Mr. Balachandran will oversee all operational aspects of the company including manufacturing […]

For inquiries, please visit our Contact Page.